I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

This will be Sanofi's largest single investment in China since entering the country in 1982. Sanofi has not been alone ...

Sanofi is increasing its R&D presence in China, announcing plans to open a global research hub focused on data analysis in Chengdu. The French firm said this confirms China as the “third pillar ...

Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV’574), met its primary endpoints.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten ...

Investing.com -- Shares of Cytokinetics (NASDAQ: CYTK ), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (EPA: SASY) (NASDAQ: SNY) will acquire exclusive rights to ...

Sanofi will now acquire CORXEL's rights relating to aficamten in Greater China for an undisclosed amount. Cytokinetics remains eligible to receive up to $150 million in development and commercial ...